| abstract |
Formula (I) to (VIII) The compound or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug is disclosed in, where R 3 is when the tree is substituted by R 3a and 0-2 R 3b A heterocyclic aryl group; R 1 , R 2 , R 3a , R 3b , R 4 , and n are defined in the first aspect. Methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds, are also disclosed. These compounds are useful for inhibiting or preventing platelet aggregation and are useful for the treatment of thromboembolic disorders or for the primary prevention of thromboembolic disorders. |